Details of the Drug Reposition

General Information of This Drug (ID: DMD7K9X)

Drug Name
Davunetide   DMD7K9X
Synonyms
Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cognitive impairment DISH2ERD 6D71 Phase 3 [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Alzheimer disease DISF8S70 8A20 Discontinued in Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014948)